Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EP300 | Q09472 | 16/20 | 0.67 |
| ▸ | CREBBP | Q92793 | 9/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21874035 | 0.96 | EP300 (0.70) | EP300CREBBPCYP3A4CYP2C19SIGMAR1 | |
| SCHEMBL21874036 | 0.96 | EP300 (0.70) | EP300CREBBPCYP3A4CYP2C19SIGMAR1 | |
| SCHEMBL23485422 | 0.95 | EP300 (0.71) | EP300CREBBPCYP3A4CYP2C19SIGMAR1 | |
| SCHEMBL21874004 | 0.95 | EP300 (0.71) | EP300CREBBPCYP3A4CYP2C19SIGMAR1 | |
| SCHEMBL21873961 | 0.86 | EP300 (0.70) | EP300CREBBPCYP3A4CYP2C19KMT2A | |
| SCHEMBL21873958 | 0.86 | EP300 (0.70) | EP300CREBBPCYP3A4CYP2C19KMT2A | |
| SCHEMBL29510688 | 0.86 | EP300 (0.61) | EP300CREBBPCYP3A4CYP2C19SIGMAR1 | |
| SCHEMBL23485252 | 0.83 | EP300 (0.58) | EP300CREBBPCYP3A4CYP2C19SIGMAR1 | |
| SCHEMBL25382199 | 0.82 | LGMN (0.57) | EP300CREBBP | |
| SCHEMBL30565506 | 0.82 | LGMN (0.57) | EP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3643703-A1 | EP300/CREBBP INHIBITOR | Daiichi Sankyo Co., Ltd. (JP) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | EP300 1/4885CREBBP 2/4885CYP3A4 4303/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | EP300 1/4885CREBBP 2/4885CYP3A4 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.